1. Home
  2. CCSI vs PHAT Comparison

CCSI vs PHAT Comparison

Compare CCSI & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Consensus Cloud Solutions Inc.

CCSI

Consensus Cloud Solutions Inc.

BUY

Current Price

$35.62

Market Cap

648.0M

Sector

Technology

ML Signal

BUY

Logo Phathom Pharmaceuticals Inc.

PHAT

Phathom Pharmaceuticals Inc.

SELL

Current Price

$6.82

Market Cap

590.6M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CCSI
PHAT
Founded
2021
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
648.0M
590.6M
IPO Year
2022
2019

Fundamental Metrics

Financial Performance
Metric
CCSI
PHAT
Price
$35.62
$6.82
Analyst Decision
Strong Buy
Buy
Analyst Count
4
12
Target Price
★ $42.25
$20.45
AVG Volume (30 Days)
100.8K
★ 1.2M
Earning Date
11-05-2026
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 42.72
EPS
★ 2.72
N/A
Revenue
★ $349,696,000.00
$175,110,000.00
Revenue This Year
$3.01
$80.50
Revenue Next Year
$3.66
$56.64
P/E Ratio
$13.30
★ N/A
Revenue Growth
N/A
★ 216.93
52 Week Low
$20.20
$6.52
52 Week High
$41.40
$18.31

Technical Indicators

Market Signals
Indicator
CCSI
PHAT
Relative Strength Index (RSI) 47.54 32.80
Support Level $32.99 N/A
Resistance Level $35.89 $9.74
Average True Range (ATR) 1.14 0.36
MACD 0.09 -0.02
Stochastic Oscillator 59.12 20.27

Price Performance

Historical Comparison
CCSI
PHAT

About CCSI Consensus Cloud Solutions Inc.

Consensus Cloud Solutions Inc is a provider of secure information delivery services with a scalable Software-as-a-Service SaaS platform. It is engaged in the fax cloud business. The company's offerings include communication, data extraction, and digital signature solutions that enable users to securely access, exchange, and manage information across organizational and geographic boundaries. It serves multiple industry verticals, including healthcare, government, financial services, legal, and education. Geographically, the company operates in the United States, Canada, Ireland, and other countries. It derives the maximum revenue from the United States.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: